Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
44.44
-0.41 (-0.91%)
Apr 25, 2025, 12:29 PM EDT - Market open
Protagonist Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 97.25 | 186.73 | 125.74 | 123.67 | 117.36 | Upgrade
|
| Short-Term Investments | 321.66 | 154.89 | 111.61 | 203.24 | 188.45 | Upgrade
|
| Cash & Short-Term Investments | 418.91 | 341.62 | 237.36 | 326.9 | 305.81 | Upgrade
|
| Cash Growth | 22.63% | 43.93% | -27.39% | 6.90% | 129.90% | Upgrade
|
| Accounts Receivable | 165 | 10 | 0.01 | 1.57 | 2.43 | Upgrade
|
| Other Receivables | 3.49 | 0.33 | 0.04 | 3.77 | 1.4 | Upgrade
|
| Receivables | 168.49 | 10.33 | 0.05 | 5.33 | 3.82 | Upgrade
|
| Prepaid Expenses | 4.24 | 3.63 | 5.67 | 8.5 | 5.97 | Upgrade
|
| Restricted Cash | - | - | - | - | 0.01 | Upgrade
|
| Total Current Assets | 591.64 | 355.58 | 243.08 | 340.74 | 315.61 | Upgrade
|
| Property, Plant & Equipment | 12.61 | 2.15 | 4.63 | 6.73 | 6.41 | Upgrade
|
| Long-Term Investments | 140.25 | - | - | - | 2 | Upgrade
|
| Other Long-Term Assets | 0.23 | 0.23 | 0.23 | 0.23 | 0.45 | Upgrade
|
| Total Assets | 744.73 | 357.95 | 247.93 | 347.7 | 324.47 | Upgrade
|
| Accounts Payable | 1.62 | 0.77 | 3.64 | 1.6 | 3.08 | Upgrade
|
| Accrued Expenses | 23.62 | 19.26 | 24.54 | 37.31 | 18.42 | Upgrade
|
| Current Portion of Leases | 0.51 | 1.14 | 2.52 | 2.2 | 1.46 | Upgrade
|
| Current Income Taxes Payable | 2.69 | - | - | - | - | Upgrade
|
| Current Unearned Revenue | 18.89 | - | - | 1.6 | 14.48 | Upgrade
|
| Other Current Liabilities | 0.07 | 0.1 | 0.48 | 1.31 | 2.81 | Upgrade
|
| Total Current Liabilities | 47.4 | 21.27 | 31.18 | 44.02 | 40.24 | Upgrade
|
| Long-Term Leases | 10.36 | - | 1.14 | 3.66 | 4.5 | Upgrade
|
| Long-Term Unearned Revenue | 11.68 | - | - | - | - | Upgrade
|
| Other Long-Term Liabilities | - | - | - | - | 0.12 | Upgrade
|
| Total Liabilities | 69.43 | 21.27 | 32.32 | 47.67 | 44.86 | Upgrade
|
| Common Stock | 0 | 0 | - | - | - | Upgrade
|
| Additional Paid-In Capital | 1,016 | 952.49 | 752.72 | 709.68 | 563.39 | Upgrade
|
| Retained Earnings | -340.52 | -615.71 | -536.76 | -409.36 | -283.81 | Upgrade
|
| Comprehensive Income & Other | -0.08 | -0.11 | -0.36 | -0.3 | 0.03 | Upgrade
|
| Total Common Equity | 675.3 | 336.68 | 215.61 | 300.02 | 279.61 | Upgrade
|
| Shareholders' Equity | 675.3 | 336.68 | 215.61 | 300.02 | 279.61 | Upgrade
|
| Total Liabilities & Equity | 744.73 | 357.95 | 247.93 | 347.7 | 324.47 | Upgrade
|
| Total Debt | 10.87 | 1.14 | 3.66 | 5.86 | 5.96 | Upgrade
|
| Net Cash (Debt) | 548.3 | 340.48 | 233.7 | 321.04 | 301.85 | Upgrade
|
| Net Cash Growth | 61.04% | 45.69% | -27.21% | 6.36% | 160.20% | Upgrade
|
| Net Cash Per Share | 8.43 | 6.00 | 4.77 | 6.93 | 8.78 | Upgrade
|
| Filing Date Shares Outstanding | 61.38 | 58.27 | 51.28 | 48.41 | 43.81 | Upgrade
|
| Total Common Shares Outstanding | 61.04 | 57.71 | 49.34 | 47.84 | 43.75 | Upgrade
|
| Working Capital | 544.24 | 334.3 | 211.9 | 296.72 | 275.37 | Upgrade
|
| Book Value Per Share | 11.06 | 5.83 | 4.37 | 6.27 | 6.39 | Upgrade
|
| Tangible Book Value | 675.3 | 336.68 | 215.61 | 300.02 | 279.61 | Upgrade
|
| Tangible Book Value Per Share | 11.06 | 5.83 | 4.37 | 6.27 | 6.39 | Upgrade
|
| Machinery | 7.8 | 6.47 | 5.91 | 5.18 | 4.19 | Upgrade
|
| Leasehold Improvements | 2.42 | 0.96 | 0.91 | 0.88 | 0.75 | Upgrade
|
Updated Feb 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.